Paclinab is a microtubule inhibitor indicated for the treatment of patients with Metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, Metastatic adenocarcinoma of pancreas.
It is recommended by guidelines such as NCCN and ESMO as first-line regimens in metastatic pancreatic cancer in combination with gemcitabine and in non-small cell lung cancer in combination with carboplatin.
INDICATION
Metastatic Breast Cancer: Paclinab is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Non-Small Cell Lung Cancer: Paclinab is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Adenocarcinoma of the Pancreas: Pacl
Show More
